Endorsement of New Drugs

Image

1) Zeposia (ozanimod) Capsules

Company: Bristol-Myers Squibb Company

Date of Approval: March 25, 2020

Treatment for: Multiple Sclerosis

Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

 

2) Isturisa (osilodrostat) Tablets

Company: Novartis Pharmaceuticals Corporation

Date of Approval: March 6, 2020

Treatment for: Cushing's Syndrome

Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.

 

3) Durysta (bimatoprost) Implant

Company: Allergan plc

Date of Approval: March 3, 2020

Treatment for: Glaucoma (Open Angle), Intraocular Hypertension

Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

 

5) Advil Dual Action (ibuprofen and acetaminophen) Tablets

Company: GlaxoSmithKline Consumer Healthcare LP

Date of Approval: February 28, 2020

Treatment for: Pain

Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain.

 

6) Nurtec ODT (rimegepant) Orally Disintegrating Tablets

Company: Biohaven Pharmaceutical Holding Company Ltd.

Date of Approval: February 27, 2020

Treatment for: Migraine

Nurtec ODT (rimegepant) is an orally-dosed calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine.

 

7) Nexlizet (bempedoic acid and ezetimibe) Tablets

Company: Esperion Therapeutics

Date of Approval: February 26, 2020

Treatment for: Heterozygous Familial Hypercholesterolemia

Nexlizet (bempedoic acid and ezetimibe) is an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor combination indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

 

8) Barhemsys (amisulpride) Injection

Company: Acacia Pharma

Date of Approval: February 26, 2020

Treatment for: Nausea/Vomiting -- Postoperative

Barhemsys (amisulpride) is a dopamine antagonist for the management of post-operative nausea & vomiting (PONV).

 

9) Nexletol (bempedoic acid) Tablets

Company: Esperion Therapeutics, Inc.

Date of Approval: February 21, 2020

Treatment for: Heterozygous Familial Hypercholesterolemia

Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol.

 

10) Vyepti (eptinezumab-jjmr) Injection

Company: Lundbeck Inc.

Date of Approval: February 21, 2020

Treatment for: Migraine Prophylaxis

Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the prevention of migraine in adults.

 

11) Anjeso (meloxicam) Injection

Company: Baudax Bio, Inc.

Date of Approval: February 20, 2020

Treatment for: Pain

Anjeso (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) injection indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics

 

Media Contact: 

Allison Grey 

Journal Manager 

Journal of Clinical chemistry and Laboratory Medicne

Email: jcclm@molecularbiol.com